

# Eric Solary

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6524965/publications.pdf>

Version: 2024-02-01

368  
papers

32,648  
citations

3933

88  
h-index

5120

166  
g-index

391  
all docs

391  
docs citations

391  
times ranked

37076  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2022, 139, 1066-1079.	1.4	24
2	UBA1 gene mutation in giant cell arteritis. <i>Clinical Rheumatology</i> , 2022, 41, 1257-1259.	2.2	6
3	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2 <sup>low</sup> resting monocytes. <i>Communications Biology</i> , 2022, 5, 110.	4.4	8
4	Reprogramming monocyte-derived macrophages through caspase inhibition. <i>Oncolmmunology</i> , 2022, 11, 2015859.	4.6	3
5	Ageing and cancer: a research gap to fill. <i>Molecular Oncology</i> , 2022, 16, 3220-3237.	4.6	7
6	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. <i>EBioMedicine</i> , 2022, 80, 104077.	6.1	7
7	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
8	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. <i>Blood</i> , 2022, 140, 1408-1418.	1.4	13
9	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. <i>Leukemia</i> , 2021, 35, 893-896.	7.2	3
10	Identifying key questions in the ecology and evolution of cancer. <i>Evolutionary Applications</i> , 2021, 14, 877-892.	3.1	58
11	Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting. <i>European Journal of Health Economics</i> , 2021, 22, 855-864.	2.8	10
12	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 258.	6.3	113
13	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 54.	6.2	5
14	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021, 12, 2901.	12.8	44
15	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 2739-2751.	7.2	10
16	Cytokine-like protein 1 $\alpha$ -induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. <i>Blood</i> , 2021, 137, 3390-3402.	1.4	16
17	Chronic Myelomonocytic Leukemia Gold Jubilee. <i>Hemato</i> , 2021, 2, 403-428.	0.6	0
18	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	11.2	31

#	ARTICLE	IF	CITATIONS
19	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN $\gamma$ in myeloproliferative neoplasms. <i>Blood</i> , 2021, 138, 2231-2243.	1.4	25
20	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2020, 105, 112-123.	3.5	13
21	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	7.0	114
22	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€”a study of 1084 patients. <i>Leukemia</i> , 2020, 34, 1407-1421.	7.2	68
23	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102446.	5.8	13
24	Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101134.	1.7	8
25	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	3.4	21
26	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020, 14, 1589-1615.	4.6	33
27	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020, 182, 1401-1418.e18.	28.9	663
28	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	5.4	16
29	Tracking chronic myelomonocytic leukaemia diversity at the single cell level. <i>EBioMedicine</i> , 2020, 59, 102935.	6.1	0
30	Immune responses during COVID-19 infection. <i>Oncolmmunology</i> , 2020, 9, 1807836.	4.6	103
31	No impact of cancer and plague-relevant <i>FPR1</i> polymorphisms on COVID-19. <i>Oncolmmunology</i> , 2020, 9, 1857112.	4.6	4
32	Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state. <i>Haematologica</i> , 2020, 105, e147-e152.	3.5	19
33	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. <i>Oncogene</i> , 2020, 39, 5323-5337.	5.9	12
34	The role of host environment in cancer evolution. <i>Evolutionary Applications</i> , 2020, 13, 1756-1770.	3.1	15
35	Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 209-211.	0.4	7
36	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <sc>SARSâ€CoV</sc>â€2 pandemic. <i>American Journal of Hematology</i> , 2020, 95, E203-E208.	4.1	10

#	ARTICLE	IF	CITATIONS
37	Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study. <i>Blood</i> , 2020, 136, 15-16.	1.4	2
38	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dakota Trial. <i>Blood</i> , 2020, 136, 53-54.	1.4	24
39	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. <i>Leukemia</i> , 2019, 33, 205-216.	7.2	39
40	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. <i>Cell Reports</i> , 2019, 28, 3381-3394.e7.	6.4	28
41	Towards a classification of stem cells. <i>ELife</i> , 2019, 8, .	6.0	34
42	Using healthcare claims data to analyze the prevalence of BCR-ABL positive chronic myeloid leukemia in France: A nationwide population-based study. <i>Cancer Medicine</i> , 2019, 8, 3296-3304.	2.8	10
43	Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages. <i>Nature Communications</i> , 2019, 10, 1935.	12.8	25
44	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2019, 33, 2466-2480.	7.2	66
45	Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia. <i>Journal of Molecular Medicine</i> , 2019, 97, 633-645.	3.9	15
46	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. <i>Blood</i> , 2019, 133, 2718-2724.	1.4	31
47	MUB40 Binds to Lactoferrin and Stands as a Specific Neutrophil Marker. <i>Cell Chemical Biology</i> , 2018, 25, 483-493.e9.	5.2	13
48	Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2503-2505.	1.3	4
49	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018, 92, 1-10.	2.8	14
50	High sensitivity of the Hematoflow <sup>®</sup> solution for chronic myelomonocytic leukemia screening. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 814-817.	1.5	8
51	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1742-1745.	1.3	6
52	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. <i>Blood Cancer Journal</i> , 2018, 8, 114.	6.2	16
53	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. <i>HemaSphere</i> , 2018, 2, e150.	2.7	91
54	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. <i>Nature Communications</i> , 2018, 9, 5455.	12.8	33

#	ARTICLE	IF	CITATIONS
55	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. <i>European Journal of Cancer</i> , 2018, 103, 108-119.	2.8	18
56	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 82.	6.2	24
57	Does being overweight contribute to longer survival rates in myelodysplastic syndrome?. <i>Haematologica</i> , 2018, 103, 559-560.	3.5	0
58	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. , 2018, , 563-563.		0
59	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018, 31, 174-181.	6.1	72
60	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 153-162.	2.0	17
61	Chronic Myelomonocytic Leukemia (CMML). <i>Hematologic Malignancies</i> , 2018, , 65-79.	0.2	0
62	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12
63	Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. <i>Leukemia Research</i> , 2017, 55, 58-64.	0.8	5
64	Non-apoptotic functions of caspases in myeloid cell differentiation. <i>Cell Death and Differentiation</i> , 2017, 24, 1337-1347.	11.2	36
65	CMML: Clinical and molecular aspects. <i>International Journal of Hematology</i> , 2017, 105, 711-719.	1.6	38
66	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	12.8	55
67	Turning the tide in myelodysplastic/myeloproliferative neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 425-440.	28.4	117
68	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2875-2879.	1.3	3
69	DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues. <i>Cell Death and Disease</i> , 2017, 8, e2816-e2816.	6.3	20
70	How I treat chronic myelomonocytic leukemia. <i>Blood</i> , 2017, 130, 126-136.	1.4	93
71	NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy. <i>Cell Death and Differentiation</i> , 2017, 24, 1632-1644.	11.2	50
72	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. <i>Blood</i> , 2017, 130, 832-835.	1.4	55

#	ARTICLE	IF	CITATIONS
73	A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease. <i>Human Molecular Genetics</i> , 2017, 26, 4680-4688.	2.9	8
74	Resveratrol stimulates the metabolic reprogramming of human CD4 <sup>+</sup> T cells to enhance effector function. <i>Science Signaling</i> , 2017, 10, .	3.6	29
75	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. <i>Blood Cancer Journal</i> , 2017, 7, e584-e584.	6.2	68
76	Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. <i>Blood Cancer Journal</i> , 2017, 7, e562-e562.	6.2	14
77	Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells. <i>Oncotarget</i> , 2017, 8, 37681-37693.	1.8	41
78	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. <i>Oncotarget</i> , 2017, 8, 54082-54095.	1.8	25
79	Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. <i>Blood Advances</i> , 2017, 1, 972-979.	5.2	25
80	The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease Treatment. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 246.	2.9	8
81	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188174.	2.5	85
82	The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. <i>Blood Advances</i> , 2017, 1, 1959-1976.	5.2	34
83	Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease. <i>JCI Insight</i> , 2017, 2, e90531.	5.0	11
84	Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis. <i>Oncotarget</i> , 2016, 7, 28160-28168.	1.8	66
85	Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. <i>PLoS ONE</i> , 2016, 11, e0160165.	2.5	8
86	Transfer of functional microRNAs between glioblastoma and microvascular endothelial cells through gap junctions. <i>Oncotarget</i> , 2016, 7, 73925-73934.	1.8	42
87	Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 147-154.	7.4	8
88	Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 3707-3709.	7.0	9
89	CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. <i>Scientific Reports</i> , 2016, 6, 37827.	3.3	69
90	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. <i>Blood</i> , 2016, 127, 749-760.	1.4	36

#	ARTICLE	IF	CITATIONS
91	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016, 7, 10767.	12.8	177
92	The guardians of inherited oncogenic vulnerabilities. <i>Evolution; International Journal of Organic Evolution</i> , 2016, 70, 1-6.	2.3	10
93	The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development. <i>Oncogene</i> , 2016, 35, 2842-2851.	5.9	20
94	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2016, 128, 109-109.	1.4	2
95	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. <i>Blood</i> , 2016, 128, 4320-4320.	1.4	5
96	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. <i>Stem Cells</i> , 2015, 33, 2887-2892.	3.2	8
97	Cancer: an emergent property of disturbed resource-rich environments? Ecology meets personalized medicine. <i>Evolutionary Applications</i> , 2015, 8, 527-540.	3.1	23
98	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. <i>Blood</i> , 2015, 125, 930-940.	1.4	87
99	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015, 125, 1857-1865.	1.4	153
100	Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. <i>Blood</i> , 2015, 126, 1106-1117.	1.4	399
101	Can Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. <i>BMC Cancer</i> , 2015, 15, 792.	2.6	17
102	The Impact of Tumor Nitric Oxide Production on VEGFA Expression and Tumor Growth in a Zebrafish Rat Glioma Xenograft Model. <i>PLoS ONE</i> , 2015, 10, e0120435.	2.5	17
103	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0126526.	2.5	10
104	The PRKAA1/AMPK $\pm$ 1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. <i>Autophagy</i> , 2015, 11, 1114-1129.	9.1	86
105	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. <i>Blood Cancer Journal</i> , 2015, 5, e270-e270.	6.2	39
106	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 3618-3626.	1.4	197
107	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. <i>Blood Cancer Journal</i> , 2015, 5, e333-e333.	6.2	117
108	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2015, 100, 1117-1130.	3.5	97

#	ARTICLE	IF	CITATIONS
109	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. <i>Nature Genetics</i> , 2015, 47, 1131-1140.	21.4	107
110	Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. <i>Leukemia</i> , 2015, 29, 249-252.	7.2	88
111	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015, 125, 1857-1872.	8.2	151
112	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. <i>Blood</i> , 2015, 126, 2872-2872.	1.4	1
113	H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway. <i>Oncotarget</i> , 2015, 6, 6877-6886.	1.8	12
114	Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells. <i>Oncotarget</i> , 2015, 6, 10267-10283.	1.8	14
115	Primary tumor- and metastasis-derived colon cancer cells differently modulate connexin expression and function in human capillary endothelial cells. <i>Oncotarget</i> , 2015, 6, 28800-28815.	1.8	36
116	French consensus on myelodysplastic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. <i>Hematologie</i> , 2015, 21, 28-45.	0.0	1
117	HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia?. <i>Blood</i> , 2015, 126, 671-671.	1.4	0
118	Differential Effects of CSF-1R D802V and KIT D816V Homologous Mutations on Receptor Tertiary Structure and Allosteric Communication. <i>PLoS ONE</i> , 2014, 9, e97519.	2.5	11
119	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. <i>Leukemia</i> , 2014, 28, 2206-2212.	7.2	237
120	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a multicenter study. <i>American Journal of Hematology</i> , 2014, 89, 1111-1115.	4.1	129
121	The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. <i>Cell Death and Disease</i> , 2014, 5, e1533-e1533.	6.3	57
122	A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 1785-1794.	3.3	32
123	Circulating Immature Granulocytes With T-Cell Killing Functions Predict Sepsis Deterioration*. <i>Critical Care Medicine</i> , 2014, 42, 2007-2018.	0.9	156
124	Editorial: The emerging specificities of interleukin-34. <i>Journal of Leukocyte Biology</i> , 2014, 95, 3-5.	3.3	2
125	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 604-609.	4.1	36
126	JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. <i>Leukemia</i> , 2014, 28, 338-348.	7.2	137



#	ARTICLE	IF	CITATIONS
127	Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFN $\alpha$ treatment. <i>Leukemia</i> , 2014, 28, 460-463.	7.2	12
128	The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. <i>Leukemia</i> , 2014, 28, 485-496.	7.2	235
129	cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation. <i>Oncogene</i> , 2014, 33, 5534-5545.	5.9	22
130	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. <i>Blood</i> , 2014, 123, 1372-1383.	1.4	69
131	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. <i>Cancer Discovery</i> , 2014, 4, 1088-1101.	9.4	213
132	Serum 2-Hydroxyglutarate Production in <i>IDH1</i> - and <i>IDH2</i> -Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 297-305.	1.6	109
133	SFP CO-61 - Etude de l'effet de l'interféron-gamma dans le syndrome hémophagocytaire des hémopathies lymphoïdes. <i>Archives De Pédiatrie</i> , 2014, 21, 639.	1.0	0
134	Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 301-310.	2.3	2
135	Dual regulation of SPI1/PU.1 transcription factor by heat shock factor 1 (HSF1) during macrophage differentiation of monocytes. <i>Leukemia</i> , 2014, 28, 1676-1686.	7.2	30
136	Cohen syndrome is associated with major glycosylation defects. <i>Human Molecular Genetics</i> , 2014, 23, 2391-2399.	2.9	79
137	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. <i>Stem Cells</i> , 2014, 32, 2084-2097.	3.2	34
138	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. <i>Blood</i> , 2014, 124, 2104-2115.	1.4	45
139	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. <i>Journal of Clinical Investigation</i> , 2014, 124, 580-591.	8.2	163
140	Targeting apoptosis proteins in hematological malignancies. <i>Cancer Letters</i> , 2013, 332, 325-334.	7.2	27
141	An evolutionary perspective on chronic myelomonocytic leukemia. <i>Leukemia</i> , 2013, 27, 1441-1450.	7.2	81
142	Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. <i>FASEB Journal</i> , 2013, 27, 4169-4183.	0.5	93
143	Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 387-400.	1.7	14
144	Clonal architecture of chronic myelomonocytic leukemias. <i>Blood</i> , 2013, 121, 2186-2198.	1.4	232

#	ARTICLE	IF	CITATIONS
145	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2428-2436.	1.6	462
146	A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1936-1946.	4.1	43
147	Applying ecological and evolutionary theory to cancer: a long and winding road. <i>Evolutionary Applications</i> , 2013, 6, 1-10.	3.1	70
148	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. <i>Leukemia</i> , 2013, 27, 1401-1403.	7.2	102
149	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. <i>Immunity</i> , 2013, 38, 729-741.	14.3	572
150	ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1101-1110.	27.0	342
151	A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression. <i>Leukemia</i> , 2013, 27, 2187-2195.	7.2	154
152	Developmental changes in human megakaryopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1730-1741.	3.8	68
153	Epigenetic Control of NF- $\kappa$ B-Dependent <i>FAS</i> Gene Transcription during Progression of Myelodysplastic Syndromes. <i>Molecular Cancer Research</i> , 2013, 11, 724-735.	3.4	14
154	TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. <i>EMBO Journal</i> , 2013, 32, 645-655.	7.8	411
155	Tubulin-targeting agent combination therapies: dosing schedule could matter. <i>British Journal of Pharmacology</i> , 2013, 168, 1555-1557.	5.4	3
156	Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2013, 27, 1946-1949.	7.2	35
157	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. <i>Cell Death and Disease</i> , 2013, 4, e738-e738.	6.3	30
158	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. <i>Blood</i> , 2013, 122, 3169-3177.	1.4	169
159	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN- $\gamma$ . <i>Blood</i> , 2013, 122, 1464-1477.	1.4	122
160	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	3.5	50
161	Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. <i>PLoS ONE</i> , 2013, 8, e74257.	2.5	32
162	Recent advances in chronic myelomonocytic leukemia. <i>Hematologie</i> , 2012, 18, 24-36.	0.0	0

#	ARTICLE	IF	CITATIONS
163	Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. <i>Leukemia</i> , 2012, 26, 2297-2299.	7.2	25
164	CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. <i>Cell Death and Disease</i> , 2012, 3, e396-e396.	6.3	53
165	Current insights in the cellular and molecular biology of chronic myelomonocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 147-158.	1.6	1
166	Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. <i>Blood</i> , 2012, 119, 1532-1542.	1.4	61
167	Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. <i>Blood</i> , 2012, 119, 4527-4531.	1.4	123
168	When monocyte life hangs by a thread. <i>Blood</i> , 2012, 119, 2699-2700.	1.4	3
169	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. <i>Blood</i> , 2012, 120, 2719-2722.	1.4	68
170	JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. <i>Oncogene</i> , 2012, 31, 1323-1333.	5.9	104
171	Proper macrophagic differentiation requires both autophagy and caspase activation. <i>Autophagy</i> , 2012, 8, 1141-1143.	9.1	38
172	Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2853-2861.	5.4	4
173	Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Oncotarget</i> , 2012, 3, 1284-1293.	1.8	19
174	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. <i>Blood Cancer Journal</i> , 2011, 1, e7-e7.	6.2	13
175	TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT. <i>PLoS ONE</i> , 2011, 6, e19679.	2.5	57
176	A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly. <i>PLoS ONE</i> , 2011, 6, e29058.	2.5	33
177	Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. <i>Haematologica</i> , 2011, 96, 612-616.	3.5	106
178	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. <i>Blood</i> , 2011, 117, 3065-3075.	1.4	45
179	Fine-tuning nucleophosmin in macrophage differentiation and activation. <i>Blood</i> , 2011, 118, 4694-4704.	1.4	39
180	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. <i>Blood</i> , 2011, 118, 3824-3831.	1.4	187

#	ARTICLE	IF	CITATIONS
181	Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. <i>Cell Death and Differentiation</i> , 2011, 18, 700-711.	11.2	75
182	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 25-38.	16.8	792
183	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 276.	16.8	3
184	Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe. <i>Current Medicinal Chemistry</i> , 2011, 18, 1100-1121.	2.4	144
185	Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription. <i>Journal of Biological Chemistry</i> , 2011, 286, 26406-26417.	3.4	40
186	Transactivation of the Epidermal Growth Factor Receptor by Heat Shock Protein 90 via Toll-like Receptor 4 Contributes to the Migration of Glioblastoma Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 3418-3428.	3.4	86
187	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. <i>Blood</i> , 2011, 118, 2551-2555.	1.4	163
188	Endocytosis of Resveratrol via Lipid Rafts and Activation of Downstream Signaling Pathways in Cancer Cells. <i>Cancer Prevention Research</i> , 2011, 4, 1095-1106.	1.5	86
189	Transcription intermediary factor 1 $\beta$ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2011, 121, 2361-2370.	8.2	91
190	Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. <i>Blood</i> , 2010, 115, 78-88.	1.4	44
191	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , 2010, 115, 1690-1696.	1.4	232
192	HSP27 controls GATA-1 protein level during erythroid cell differentiation. <i>Blood</i> , 2010, 116, 85-96.	1.4	66
193	Comparative analysis of nonspanin protein sequences and expression studies in zebrafish. <i>Immunogenetics</i> , 2010, 62, 681-699.	2.4	12
194	The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. <i>Oncogene</i> , 2010, 29, 2577-2584.	5.9	42
195	Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. <i>Oncogene</i> , 2010, 29, 5019-5031.	5.9	48
196	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 1094-1096.	7.2	225
197	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 457-71.	8.2	761
198	Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 1876-1884.	0.8	58

#	ARTICLE	IF	CITATIONS
199	Editorial: CSF1R, CSF-1, and IL-34, a "conserved across vertebrates. Journal of Leukocyte Biology, 2010, 87, 745-747.	3.3	53
200	Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML. Blood, 2010, 116, 3997-3997.	1.4	3
201	Various functions of caspases in hematopoiesis. Frontiers in Bioscience - Landmark, 2009, Volume, 2358.	3.0	6
202	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	3.5	234
203	Liver X Receptor-Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1923-1929.	2.4	21
204	Induction of Transglutaminase 2 by a Liver X Receptor/Retinoic Acid Receptor Pathway Increases the Clearance of Apoptotic Cells by Human Macrophages. Circulation Research, 2009, 105, 393-401.	4.5	96
205	Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluorouracil sensitivity in human derived colon cancer cells. International Journal of Cancer, 2009, 124, 2780-2788.	5.1	122
206	C020 Prevalence of TET2 mutations in MDS. Leukemia Research, 2009, 33, S43-S44.	0.8	0
207	Human defensins as cancer biomarkers and antitumour molecules. Journal of Proteomics, 2009, 72, 918-927.	2.4	128
208	Comparative analysis of zebrafish nos2a and nos2b genes. Gene, 2009, 445, 58-65.	2.2	63
209	cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand. Blood, 2009, 113, 175-185.	1.4	35
210	FAS-L, IL-10, and double-negative CD4 <sup>+</sup> CD8 <sup>-</sup> TCR <sup>+</sup> T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood, 2009, 113, 3027-3030.	1.4	134
211	Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. Blood, 2009, 114, 3633-3641.	1.4	51
212	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	1.4	264
213	Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biology International, 2008, 32, 1031-1043.	3.0	213
214	Trefoil Factor TFF1-Induced Protection of Conjunctival Cells from Apoptosis at Premitochondrial and Postmitochondrial Levels. , 2008, 49, 3790.		14
215	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia, 2008, 22, 1864-1873.	7.2	27
216	Interaction of heat-shock protein 90 <sup>β</sup> isoform (HSP90 <sup>β</sup> ) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death and Differentiation, 2008, 15, 859-866.	11.2	45

#	ARTICLE	IF	CITATIONS
217	Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. <i>Cancer Gene Therapy</i> , 2008, 15, 742-749.	4.6	11
218	Re-examining the role of cytochrome c in cell death. <i>Nature Genetics</i> , 2008, 40, 379-380.	21.4	10
219	MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. <i>British Journal of Haematology</i> , 2008, 143, 378-382.	2.5	69
220	A role for the transcription intermediary factor 2 in zebrafish myelopoiesis. <i>Experimental Hematology</i> , 2008, 36, 559-567.	0.4	4
221	PKC zeta controls DNA topoisomerase-dependent human caspase-2 pre-mRNA splicing. <i>FEBS Letters</i> , 2008, 582, 372-378.	2.8	10
222	Heat shock proteins: essential proteins for apoptosis regulation. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 743-761.	3.6	391
223	A role for caspases in the differentiation of erythroid cells and macrophages. <i>Biochimie</i> , 2008, 90, 416-422.	2.6	27
224	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008, 118, 3751-3761.	8.2	56
225	Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism. <i>Journal of Immunology</i> , 2007, 179, 812-818.	0.8	35
226	Caspase-8 prevents sustained activation of NF- $\kappa$ B in monocytes undergoing macrophagic differentiation. <i>Blood</i> , 2007, 109, 1442-1450.	1.4	125
227	TRAIL in cancer therapy: present and future challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1299-1314.	3.4	148
228	A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2337-2345.	4.1	114
229	Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. <i>Nature</i> , 2007, 445, 102-105.	27.8	246
230	Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. <i>Clinical and Experimental Immunology</i> , 2007, 150, 523-530.	2.6	104
231	Imaging of nitric oxide in a living vertebrate using a diaminofluorescein probe. <i>Free Radical Biology and Medicine</i> , 2007, 43, 619-627.	2.9	74
232	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 641-648.	4.2	1,104
233	Fas-Dependent Apoptosis in Early MDS Erythroid Precursors Involves Endoplasmic Reticulum.. <i>Blood</i> , 2007, 110, 3346-3346.	1.4	0
234	Topoisomerase I Poisons and Apoptotic Topoisomerase I-DNA Complexes. , 2007, , 383-406.		0

#	ARTICLE	IF	CITATIONS
235	Nitric Oxide-Induced Down-Regulation of $\beta$ -Catenin in Colon Cancer Cells by a Proteasome-Independent Specific Pathway. <i>Gastroenterology</i> , 2006, 131, 1142-1152.	1.3	28
236	HSP27 favors ubiquitination and proteasomal degradation of p27 Kip1 and helps S <sub>2</sub> phase re-entry in stressed cells. <i>FASEB Journal</i> , 2006, 20, 1179-1181.	0.5	95
237	Mitochondria in hematopoiesis and hematological diseases. <i>Oncogene</i> , 2006, 25, 4757-4767.	5.9	85
238	Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. <i>Oncogene</i> , 2006, 25, 7635-7645.	5.9	28
239	Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1513-1524.	4.9	36
240	Identification of Proteins Cleaved Downstream of Caspase Activation in Monocytes Undergoing Macrophage Differentiation*. <i>Journal of Biological Chemistry</i> , 2006, 281, 17779-17788.	3.4	53
241	Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. <i>Molecular and Cellular Biology</i> , 2006, 26, 7046-7055.	2.3	288
242	Differential Mechanisms of Conjunctival Cell Death Induction by Ultraviolet Irradiation and Benzalkonium Chloride. , 2006, 47, 4221.		42
243	Heat Shock Protein 70 Neutralization Exerts Potent Antitumor Effects in Animal Models of Colon Cancer and Melanoma. <i>Cancer Research</i> , 2006, 66, 4191-4197.	0.9	138
244	Both the Endoplasmic Reticulum and the Mitochondria Are Involved in Apoptosis of Erythroid Precursors in Low Grade Myelodysplastic Syndromes.. <i>Blood</i> , 2006, 108, 2638-2638.	1.4	0
245	Essential role for the p110 $\beta$ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. <i>Blood</i> , 2005, 106, 1063-1066.	1.4	229
246	Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. <i>Cell Death and Differentiation</i> , 2005, 12, 687-689.	11.2	26
247	Vital functions for lethal caspases. <i>Oncogene</i> , 2005, 24, 5137-5148.	5.9	202
248	Cellular localisation of Survivin: impact on the prognosis in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 504-510.	2.5	46
249	A role for PKC $\delta$ in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1457-1464.	4.1	8
250	Caspase-2, a Novel Lipid Sensor under the Control of Sterol Regulatory Element Binding Protein 2. <i>Molecular and Cellular Biology</i> , 2005, 25, 9621-9631.	2.3	46
251	Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. <i>Journal of Experimental Medicine</i> , 2005, 201, 465-471.	8.5	191
252	Trefoil factor family mRNA and protein expression in pterygium. <i>International Journal of Oncology</i> , 2005, 27, 997.	3.3	9

#	ARTICLE	IF	CITATIONS
253	Tumor cells convert immature myeloid dendritic cells into TGF- $\beta$ -secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005, 202, 919-929.	8.5	676
254	Identification of a functional DNA binding site for the SREBP-1c transcription factor in the first intron of the human caspase-2 gene. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1738, 1-5.	2.4	13
255	Small Heat Shock Proteins HSP27 and $\beta$ -Crystallin: Cytoprotective and Oncogenic Functions. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 404-413.	5.4	144
256	Increased Immunogenicity of Colon Cancer Cells by Selective Depletion of Cytochrome c. <i>Cancer Research</i> , 2004, 64, 2705-2711.	0.9	17
257	Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. <i>Blood</i> , 2004, 104, 2035-2043.	1.4	55
258	Apoptotic Topoisomerase I-DNA Complexes Induced by Staurosporine-mediated Oxygen Radicals. <i>Journal of Biological Chemistry</i> , 2004, 279, 50499-50504.	3.4	62
259	Casein Kinase II-mediated Phosphorylation of NF- $\kappa$ B p65 Subunit Enhances Inducible Nitric-oxide Synthase Gene Transcription in Vivo. <i>Journal of Biological Chemistry</i> , 2004, 279, 23953-23960.	3.4	44
260	Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells. <i>Cancer Research</i> , 2004, 64, 3593-3598.	0.9	293
261	Analyzing Markers of Apoptosis In Vitro. , 2004, 281, 313-332.		15
262	Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. <i>Oncogene</i> , 2004, 23, 8979-8986.	5.9	181
263	CD4 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. <i>European Journal of Immunology</i> , 2004, 34, 336-344.	2.9	846
264	Tumor Cell Resistance to DNA-Damaging Agents: From Apoptosis to Neiosis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2004, 4, 461-463.	7.0	8
265	Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells. <i>Molecular Cancer Research</i> , 2004, 2, 53-61.	3.4	60
266	Subcellular Expression of c-IAP1 and c-IAP2 in Colorectal Cancers: Relationships with Clinicopathological Features and Prognosis. <i>Pathology Research and Practice</i> , 2003, 199, 723-731.	2.3	24
267	Freshly isolated bone marrow cells induce death of various carcinoma cell lines. <i>International Journal of Cancer</i> , 2003, 107, 747-756.	5.1	19
268	A role of HSPs in apoptosis through "protein triage". <i>Cell Death and Differentiation</i> , 2003, 10, 619-620.	11.2	48
269	Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. <i>Oncogene</i> , 2003, 22, 1807-1816.	5.9	117
270	The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. <i>Oncogene</i> , 2003, 22, 935-946.	5.9	49



#	ARTICLE	IF	CITATIONS
271	Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. <i>Biochemical and Biophysical Research Communications</i> , 2003, 304, 505-512.	2.1	321
272	Mitochondria as a Target for Inducing Death of Malignant Hematopoietic Cells. <i>Leukemia and Lymphoma</i> , 2003, 44, 563-574.	1.3	42
273	Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 41482-41490.	3.4	241
274	HSP27 Is a Ubiquitin-Binding Protein Involved in I $\beta$ B $\beta$ Proteasomal Degradation. <i>Molecular and Cellular Biology</i> , 2003, 23, 5790-5802.	2.3	301
275	LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level. <i>Blood</i> , 2003, 101, 194-201.	1.4	13
276	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. <i>Blood</i> , 2003, 102, 1202-1210.	1.4	84
277	Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 307-318.	7.0	31
278	Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. <i>Leukemia</i> , 2002, 16, 1154-1159.	7.2	9
279	CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS. , 2002, , 55-76.		3
280	Specific involvement of caspases in the differentiation of monocytes into macrophages. <i>Blood</i> , 2002, 100, 4446-4453.	1.4	287
281	Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. <i>Gastroenterology</i> , 2002, 123, 235-246.	1.3	71
282	Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2002, 1586, 233-242.	3.8	27
283	Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. <i>Cancer Letters</i> , 2002, 185, 181-189.	7.2	27
284	Implications physiopathologiques des altérations des gènes impliqués dans la régulation de la mort cellulaire. <i>Medecine/Sciences</i> , 2002, 18, 861-873.	0.2	0
285	Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. <i>Leukemia</i> , 2002, 16, 1569-1570.	7.2	8
286	An atypical caspase-independent death pathway for an immunogenic cancer cell line. <i>Oncogene</i> , 2002, 21, 6091-6100.	5.9	13
287	Atypical protein kinase C zeta as a target for chemosensitization of tumor cells. <i>Cancer Research</i> , 2002, 62, 1815-21.	0.9	31
288	BCR-ABL Fails to Inhibit Apoptosis in U937 Myelomonocytic Cells Expressing a Carboxyl-Terminal Truncated Stat5. <i>Leukemia and Lymphoma</i> , 2001, 42, 445-455.	1.3	5

#	ARTICLE	IF	CITATIONS
289	Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. <i>Blood</i> , 2001, 97, 1835-1844.	1.4	57
290	Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. <i>Blood</i> , 2001, 97, 3931-3940.	1.4	79
291	Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. <i>Leukemia</i> , 2001, 15, 1572-1581.	7.2	52
292	Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. <i>Oncogene</i> , 2001, 20, 260-269.	5.9	36
293	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. <i>Oncogene</i> , 2001, 20, 1852-1859.	5.9	80
294	Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. <i>Oncogene</i> , 2001, 20, 7478-7485.	5.9	77
295	Caspase Activation Is Required for Terminal Erythroid Differentiation. <i>Journal of Experimental Medicine</i> , 2001, 193, 247-254.	8.5	387
296	Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System. <i>Journal of Immunology</i> , 2001, 167, 5077-5083.	0.8	60
297	Caffeine Sensitizes Human H358 Cell Line to p53-mediated Apoptosis by Inducing Mitochondrial Translocation and Conformational Change of BAX Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 38980-38987.	3.4	40
298	Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. , 2000, 86, 827-834.		21
299	Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. <i>Leukemia</i> , 2000, 14, 1833-1849.	7.2	131
300	Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. <i>Leukemia</i> , 2000, 14, 2085-2094.	7.2	30
301	Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. <i>Oncogene</i> , 2000, 19, 4855-4863.	5.9	135
302	Hsp27 negatively regulates cell death by interacting with cytochrome c. <i>Nature Cell Biology</i> , 2000, 2, 645-652.	10.3	882
303	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , 2000, 111, 801-806.	2.5	18
304	Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway. <i>Journal of Immunology</i> , 2000, 164, 5023-5027.	0.8	72
305	Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 146-148.	0.9	16
306	Role of Tumor Cell Apoptosis in Tumor Antigen Migration to the Draining Lymph Nodes. <i>Journal of Immunology</i> , 2000, 164, 1995-2000.	0.8	42

#	ARTICLE	IF	CITATIONS
307	Dobutamine Stress Echocardiography Identifies Anthracycline Cardiotoxicity. <i>European Journal of Echocardiography</i> , 2000, 1, 180-183.	2.3	33
308	The Viral Nucleocapsid Protein of Transmissible Gastroenteritis Coronavirus (TGEV) Is Cleaved by Caspase-6 and -7 during TGEV-Induced Apoptosis. <i>Journal of Virology</i> , 2000, 74, 3975-3983.	3.4	83
309	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , 2000, 111, 801-806.	2.5	127
310	HSP27 inhibits cytochrome c-dependent activation of procaspase-9. <i>FASEB Journal</i> , 1999, 13, 2061-2070.	0.5	453
311	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 1192-1200.	1.4	682
312	Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs. <i>Journal of Biological Chemistry</i> , 1999, 274, 7987-7992.	3.4	282
313	Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. <i>Cell Death and Differentiation</i> , 1999, 6, 351-361.	11.2	49
314	A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. <i>Leukemia</i> , 1999, 13, 524-529.	7.2	49
315	p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. <i>Oncogene</i> , 1999, 18, 1411-1418.	5.9	86
316	Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. <i>Oncogene</i> , 1999, 18, 4839-4847.	5.9	84
317	FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. , 1999, 82, 359-367.		4
318	STAT-1-Independent Upregulation of FADD and Procaspase-3 and -8 in Cancer Cells Treated with Cytotoxic Drugs. <i>Biochemical and Biophysical Research Communications</i> , 1999, 256, 603-607.	2.1	61
319	Proteases, proteolysis, and apoptosis. <i>Cell Biology and Toxicology</i> , 1998, 14, 121-132.	5.3	70
320	New insights into the kinetic resistance to anticancer agents. <i>Cytotechnology</i> , 1998, 27, 225-235.	1.6	13
321	Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998, 21, 943-946.	2.4	15
322	Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate. <i>Cell Death and Differentiation</i> , 1998, 5, 480-487.	11.2	88
323	Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. <i>Leukemia</i> , 1998, 12, 34-43.	7.2	43
324	Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. <i>Oncogene</i> , 1998, 16, 2885-2894.	5.9	75

#	ARTICLE	IF	CITATIONS
325	Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. , 1998, 77, 796-802.		35
326	Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. British Journal of Haematology, 1998, 102, 1015-1024.	2.5	78
327	PreB1 (CD10<sup>-</sup>) Acute Lymphoblastic Leukemia: Immunophenotypic and Genomic Characteristics, Clinical Features and Outcome in 38 Adults and 26 Children. Leukemia and Lymphoma, 1998, 28, 329-342.	1.3	21
328	Glutathione is implied in the control of 7&acirc;ketocholesterol&acirc;induced apoptosis, which is associated with radical oxygen species production. FASEB Journal, 1998, 12, 1651-1663.	0.5	192
329	BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation. Blood, 1998, 91, 2415-2422.	1.4	92
330	BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation. Blood, 1998, 91, 2415-2422.	1.4	4
331	New insights into the kinetic resistance to anticancer agents. , 1998, , 225-235.		0
332	Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.. Journal of Clinical Oncology, 1997, 15, 139-147.	1.6	670
333	Heterogenous Expression of CD15 in Acute Lymphoblastic Leukemia: A Study of Ten Anti-CD15 Monoclonal Antibodies in 158 Patients. Leukemia and Lymphoma, 1997, 25, 135-143.	1.3	8
334	Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity. Journal of the National Cancer Institute, 1997, 89, 783-789.	6.3	273
335	Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplantation, 1997, 20, 63-65.	2.4	15
336	The role of apoptosis in the pathogenesis and treatment of diseases. European Respiratory Journal, 1996, 9, 1293-1305.	6.7	66
337	Diagnostic value of serum IL&acirc;6 level in monoclonal gammopathies. British Journal of Haematology, 1995, 89, 243-249.	2.5	34
338	Der(16)t(l;16)(qll;qll) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenetic and fluorescence in situ hybridization studies. British Journal of Haematology, 1995, 90, 119-124.	2.5	23
339	SERUM IL-6 CONCENTRATIONS IN LYMPHOMAS. British Journal of Haematology, 1995, 90, 732-732.	2.5	0
340	Diagnostic value of serum IL-6 level in monoclonal gammopathies. British Journal of Haematology, 1995, 89, 243-249.	2.5	3
341	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. International Journal of Cancer, 1995, 63, 268-275.	5.1	14
342	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. Drug Development Research, 1995, 34, 138-144.	2.9	28

#	ARTICLE	IF	CITATIONS
343	A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 603-613.	3.0	79
344	Apoptosis Induced by DNA Topoisomerase I and II Inhibitors in Human Leukemic HL-60 Cells. <i>Leukemia and Lymphoma</i> , 1994, 15, 21-32.	1.3	78
345	Prognostic Relevance of Surface Markers in Adult de novo Acute Myeloblasts Leukemias: A Prospective Study of the Groupe d'Etude Immunologique des Leucemies (G.E.I.L.). <i>Leukemia and Lymphoma</i> , 1994, 13, 7-10.	1.3	4
346	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. <i>International Journal of Cancer</i> , 1994, 58, 85-94.	5.1	15
347	Induction of a Common Pathway of Apoptosis by Staurosporine. <i>Experimental Cell Research</i> , 1994, 211, 314-321.	2.6	451
348	Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors. <i>Cancer Investigation</i> , 1994, 12, 530-542.	1.3	204
349	Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. <i>Biochemical Pharmacology</i> , 1993, 45, 2449-2456.	4.4	49
350	Apoptosis and Its Modulation in Human Promyelocytic HL-60 Cells Treated with DNA Topoisomerase I and II Inhibitors. <i>Experimental Cell Research</i> , 1993, 207, 388-397.	2.6	118
351	Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 161-169.	3.0	89
352	Prophylactic Fluconazole and <i>Candida krusei</i> Infections. <i>New England Journal of Medicine</i> , 1992, 326, 891-893.	27.0	62
353	Bone Marrow Necrosis and Human Parvovirus Associated Infection Preceding an Ph1 + Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 8, 415-419.	1.3	20
354	New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration. <i>Cancer Genetics and Cytogenetics</i> , 1992, 60, 90-92.	1.0	11
355	High Concentrations of Intrathecal Interleukin-6 in Human Bacterial and Nonbacterial Meningitis. <i>Journal of Infectious Diseases</i> , 1992, 166, 428-431.	4.0	68
356	Radiolabeling of DNA can induce its fragmentation in HL-60 human promyelocytic leukemic cells. <i>Experimental Cell Research</i> , 1992, 203, 495-498.	2.6	22
357	Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1730-1736.	1.6	103
358	Itraconazole as Salvage Therapy in Invasive Pulmonary Aspergillosis Occurring during Amphotericin B Therapy in Neutropenic Patients. <i>Chemotherapy</i> , 1992, 38, 50-51.	1.6	6
359	Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1992, 11, 722-725.	2.9	45
360	Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. <i>American Journal of Hematology</i> , 1992, 39, 163-171.	4.1	65

#	ARTICLE	IF	CITATIONS
361	Correlation of MDR1 /P&#170;170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. <i>European Journal of Haematology</i> , 1992, 48, 254-258.	2.2	32
362	Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. <i>Cancer</i> , 1991, 68, 1714-1719.	4.1	40
363	Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. <i>British Journal of Cancer</i> , 1990, 62, 395-397.	6.4	27
364	ASSOCIATION OF A CHROMOSOMAL 9.12 TRANSLOCATION WITH B CELL PRECURSOR LYMPHOBLASTIC BLAST CRISIS OF A Ph+ CHRONIC MYELOGENOUS LEUKAEMIA. <i>British Journal of Haematology</i> , 1989, 72, 106-108.	2.5	3
365	IMMUNE MECHANISMS IN HIV-RELATED NEUROPATHIES. <i>Lancet, The</i> , 1989, 334, 812-813.	13.7	0
366	DISSEMINATED ASPERGILLOSIS REVEALED BY THYROIDITIS IN A RENAL ALLOGRAFT RECIPIENT. <i>Transplantation</i> , 1987, 44, 839.	1.0	17
367	Systemic lupus erythematosus occurring in a patient with multiple myeloma. <i>Arthritis and Rheumatism</i> , 1986, 29, 933-934.	6.7	11
368	A Caspase-7/NOX2 Axis Regulates the Migration of Monocytes in Response to Colony-Stimulating Factor-1. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1